Founded in 1993
  Year: 2003 | Volume: 11 | Issue: 3 | Pages: 157-159
  Review Article
  Gastric carcinoma is a frequent malignancy throughout the world and endemic in many of its regions. Advanced gastric carcinoma is often diagnosed. Patients with advanced gastric cancer have a median survival of 6-8 months, and chemotherapy is palliative. Even in patients with resectable disease 5- year survival is generally poor. Chemotherapy is usually accepted as standard treatment for advanced disease. None of existing chemotherapy regimens has been established as standard, and chemotherapy within the controlled clinical trials is still the best option for advanced gastric cancer patients. In some trials a response rate of more than 50% has been achieved for multidrug regimens. It seems that the important story in gastric cancer is not told by focusing on the response rates in serial phase II or even phase III trials. In this disease, the success with respect to high response rates has been virtually canceled out by the fact that tumor shrinkage seems to be evanescent. There has not yet been a regimen reported that leads to a 50% survival probability at one year. A 2-year survival rate of 14% is considered noteworthy as a "long-term survival". Toxicity, including nausea, vomiting, asthenia, anorexia, neutropenia, and treatment related morbidity, in patients with gastric cancer remain substantial issues, especially with multidrug therapy. Among the newer agents, oral fluoropyrimidines, taxanes, irinotecan and oxaliplatin appear to be relevant candidates for improved palliation and extension of survival. Further clinical studies are certainly needed to define the optimal role for these drugs. Gastric carcinoma has a variety of molecular abnormalities. Many of these molecules can be targeted theoretically, however, practical applications are yet to be fully developed. Limited number of studies has been done using specific targets against gastric carcinoma.
  Key words: Stomach Neoplasms; Carcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Neoplasm Metastasis
  Read full text in PDF [Full Text]
Next article

Previous article

Table of contents

Browse all Volumes

Search all Volumes
By keywords
By authors

  Search AoO for:

  Related articles in AoO:
About Journal | Editorial Board | Editorial Policy | Instructions for Authors | Open Access | Advertising | Payed issues | Article Submission Charge | Contact
Founder, owner and publisher: Oncology Institute of Vojvodina, Serbia
Online since 1997 (Abstracts only); 2000 (Abstracts and Full text)
ISSN: 0354-7310 eISSN: 1450-9520